Acquisition Impact Private acquisition by Bio-Rad in 2020 suggests potential alignment with Bio-Rad’s customer base and distribution channels. Explore co-selling, integration opportunities, or legacy Celsee customers who may benefit from expanded single-cell platforms under Bio-Rad stewardship.

Genesis System Advantage Genesis system launch and focus on gentle, high-viability single-cell capture indicate a differentiator in accuracy and scalability. Target research groups needing large-scale single-cell analysis, including proteogenomics and transcriptomics, with demonstrations of improved cell yield and viability.

Patent and Competition Past patent litigation and related settlements with 10x Genomics highlight a competitive landscape. Position offerings around unique advantages, potential collaborations, or licensing discussions with larger players while emphasizing product stability and customer support.

Market Expansion Early platform deployment in single-cell analysis markets—immune monitoring, proteogenomics, and genomics—aligns with growing demand in biotech and clinical research. Pursue collaborations with contract research organizations and academic centers focusing on single-cell workflows.

Financial Signals Revenues in the low-to-mid single-digit millions and a lean team suggest agility but limited scale. Engage mid-size and large biotech firms with a scalable solution roadmap, offering bundled instruments, consumables, and service packages to accelerate adoption and add recurring revenue.